Barrington analyst Michael Petusky maintained a Buy rating on Lifecore Biomedical (LFCR – Research Report) today and set a price target of $10.00. The company’s shares closed yesterday at $8.05.
Petusky covers the Healthcare sector, focusing on stocks such as DENTSPLY SIRONA, Lifecore Biomedical, and Anika Therapeutics. According to TipRanks, Petusky has an average return of 6.5% and a 50.00% success rate on recommended stocks.
Currently, the analyst consensus on Lifecore Biomedical is a Moderate Buy with an average price target of $6.00.
See Insiders’ Hot Stocks on TipRanks >>
Based on Lifecore Biomedical’s latest earnings release for the quarter ending November 27, the company reported a quarterly GAAP net loss of $12.45 million. In comparison, last year the company had a net profit of $0
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Landec Corp. engages in the design, development, manufacture, and sale of health and wellness products for food and biomaterials markets. It operates through the following segments: Curation Foods, Lifecore, and Others. The Curation Foods segment includes activities to market and pack specialty packaged whole and fresh-cut fruit and vegetables. The Lifecore segment sells products utilizing hyaluronan, a naturally occurring polysaccharide that is widely distributed in the extracellular matrix of connective tissues in both animals and humans. The Other segment consists of corporate general and administrative expenses, non-Curation Foods and non-Lifecore interest income, and income tax expenses. The company was founded by Ray Stewart on October 31, 1986 and is headquartered in Santa Clara, CA.
Read More on LFCR:
- Lifecore Biomedical Sets Third Quarter 2023 Earnings Conference Call for June 1, 2023 at 7:30 a.m. CT
- Lifecore Biomedical Enters into $150.0 Million in New Financing, Repays its Outstanding Term Loans and Signs New Supply Agreement to Expand HA Fermentation Capacity with Existing Long-Term Customer
- Lifecore Biomedical, Inc. Receives Notice from Nasdaq Regarding Delayed Quarterly Report
- Lifecore receives notice from Nasdaq regarding delayed quarterly report
- Lifecore Biomedical Announces Sale of Curation Foods’ O Olive Oil and Vinegar® Business
